Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Investing Activities (2021 - 2025)

Prime Medicine (PRME) has disclosed Cash from Investing Activities for 5 consecutive years, with $28.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 41.29% year-over-year to $28.3 million, compared with a TTM value of -$108.8 million through Dec 2025, down 258.88%, and an annual FY2025 reading of -$108.8 million, down 258.88% over the prior year.
  • Cash from Investing Activities was $28.3 million for Q4 2025 at Prime Medicine, up from -$92.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $50.3 million in Q3 2024 and bottomed at -$92.1 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$3.3 million, with a median of $2.8 million recorded in 2025.
  • The sharpest move saw Cash from Investing Activities surged 401.64% in 2023, then crashed 282.99% in 2025.
  • Year by year, Cash from Investing Activities stood at $12.2 million in 2021, then tumbled by 212.61% to -$13.7 million in 2022, then soared by 401.64% to $41.3 million in 2023, then rose by 16.88% to $48.3 million in 2024, then plummeted by 41.29% to $28.3 million in 2025.
  • Business Quant data shows Cash from Investing Activities for PRME at $28.3 million in Q4 2025, -$92.1 million in Q3 2025, and $2.8 million in Q2 2025.